Isolated, perfused and ventilated guinea pig lungs were exposed to hexamethylene diisocyanate via the air passages.
Two air concentrations of hexamethylene diisocyanate were studied (3.5 and 11 mg/m3).
There was a statistically significant (P<0.05-0.001) dose-related reduction in both conductance and compliance but no effects were noted on the pulmonary circulation.
With 3.5 mg/m3 hexamethylene diisocyanate the conductance capacity was reduced with 38% and compliance with 30% after 60 min. exposure.
Eleven mg/m3 hexamethylene diisocyanate reduced the conductance and compliance capacity with 86 and 69%, respectively, on an average.
The reduction in lung function (with II mg/m3) was abolished when 100 muM diclofenac, a cyclooxygenase inhibitor, was added to the perfusate (P<0.01).
The thromboxane A2 antagonist L-670.596 (20 mum) exerted a partial protective effect.
The capacity of conductance and compliance decreased with 46 and 32% respectively, on an average, after preperfusion with L-670,596 and a following exposure of 11 mg/m3 hexamethylene diisocyanate for 60 min.
Statistically significant protection (P<0.05) was obtained on compliance and the P-value was<0.1 for conductance.
Thus, these data indicate that hexamethylene diisocyanate-induced bronchoconstriction is mediated via arachidonic acid release and thromboxane formation, in isolated, perfused and ventilated guinea pig lungs.
Mots-clés Pascal : Isocyanate organique, Industrie chimique, Exposition professionnelle, Poumon pathologie, Médecine travail, Bronchospasme, Toxicité, Animal, Cobaye, Rodentia, Mammalia, Vertebrata, Poumon, Organe isolé, Appareil respiratoire, Voie respiratoire, Mécanisme action, In vitro, Arachidonique acide dérivé, Thromboxane, Appareil respiratoire pathologie, Bronche pathologie, Hexaméthylène diisocyanate
Mots-clés Pascal anglais : Organic isocyanate, Chemical industry, Occupational exposure, Lung disease, Occupational medicine, Bronchospasm, Toxicity, Animal, Guinea pig, Rodentia, Mammalia, Vertebrata, Lung, Isolated organ, Respiratory system, Respiratory tract, Mechanism of action, In vitro, Arachidonic acid derivatives, Thromboxane, Respiratory disease, Bronchus disease
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 97-0452796
Code Inist : 002B03L06. Création : 03/02/1998.